Latest filings (excl ownership)
8-K
Regulation FD Disclosure
11 Apr 24
8-K
Regulation FD Disclosure
4 Apr 24
10-K
2023 FY
Annual report
29 Mar 24
8-K
Regulation FD Disclosure
21 Feb 24
8-K
Other Events
6 Feb 24
8-K
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
30 Jan 24
424B4
Prospectus supplement with pricing info
29 Jan 24
EFFECT
Notice of effectiveness
29 Jan 24
8-K
NGC-Cap was better tolerated with positive preliminary efficacy results than FDA-approved capecitabine
25 Jan 24
CORRESP
Correspondence with SEC
22 Jan 24
CORRESP
Correspondence with SEC
22 Jan 24
S-1/A
IPO registration (amended)
22 Jan 24
8-K
Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
19 Jan 24
8-K
Material Modifications to Rights of Security Holders
18 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
UPLOAD
Letter from SEC
5 Jan 24
S-1
IPO registration
29 Dec 23
8-K
FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU
19 Dec 23
8-K
Regulation FD Disclosure
5 Dec 23
8-K
Regulation FD Disclosure
16 Nov 23
8-K
Submission of Matters to a Vote of Security Holders
15 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Departure of Directors or Certain Officers
13 Nov 23
8-K
Regulation FD Disclosure
16 Oct 23
DEFA14A
Additional proxy soliciting materials
5 Oct 23
DEF 14A
Definitive proxy
5 Oct 23
PRE 14A
Preliminary proxy
25 Sep 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
21 Sep 23
8-K
Regulation FD Disclosure
17 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer
8 Aug 23
8-K
Amendments to Articles of Incorporation or Bylaws
29 Jun 23
8-K
Regulation FD Disclosure
21 Jun 23
8-K
Regulation FD Disclosure
24 May 23
8-K
Regulation FD Disclosure
18 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Regulation FD Disclosure
5 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
DEFA14A
Additional proxy soliciting materials
1 May 23
DEF 14A
Definitive proxy
1 May 23
Latest ownership filings
4
David Young
12 Apr 24
4
James H Stanker
12 Apr 24
4
Patrick Lin
12 Apr 24
4
Sian Bigora
12 Apr 24
4
Wendy Guy
12 Apr 24
4
David Young
8 Feb 24
4
David Young
7 Feb 24
4
Patrick Lin
1 Feb 24
4
George K Ng
31 Jan 24
4
Justin W Yorke
31 Jan 24
4
Justin W Yorke
28 Nov 23
4/A
Justin W Yorke
23 Oct 23
4
Wendy Guy
12 Oct 23
4
George K Ng
12 Oct 23
4
Patrick Lin
12 Oct 23
4
James H Stanker
12 Oct 23
4
Justin W Yorke
12 Oct 23
4
David Young
12 Oct 23
4
Geraldine Pannu
10 Oct 23
4
David Young
10 Oct 23
4
Patrick Lin
10 Oct 23
4
Justin W Yorke
10 Oct 23
4
George K Ng
10 Oct 23
4
James H Stanker
10 Oct 23
4
George K Ng
9 Aug 23
3
George K Ng
9 Aug 23
4
James R Neal
24 Jul 23
4
Justin W Yorke
24 Jul 23
4
VIRGIL THOMPSON
24 Jul 23
4
Khoso Baluch
24 Jul 23
4
Geraldine Pannu
24 Jul 23
4
David Young
12 Jun 23
4
David Young
14 Apr 23
4
David Young
13 Apr 23
4
Robert Michael Floyd
10 Feb 23
4
James H Stanker
10 Feb 23
4
Khoso Baluch
10 Feb 23
4
Patrick Lin
10 Feb 23
4
David Young
10 Feb 23
4
Justin W Yorke
4 Jan 23